Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. Vincent Ho

Vincent Ho

Professor
VCH Clinical Title(s)
Dermatologist
Research Focus
Skin Conditions
Degrees / Designations

MD, FRCPC

Contact Info
vho@interchange.ubc.ca
604-875-5151

Biography

Dr. Vincent Ho is professor at the University of British Columbia (UBC) and head of the Department of Dermatologic Oncology at the British Columbia Cancer Agency. He received his Bachelor of Science in Pharmaceutical Sciences and his MD degree from UBC. After completing his dermatology training at UBC, he obtained postgraduate training in Clinical Pharmacology and Immunodermatology (University of  Michigan) and Cutaneous Oncology (Harvard University).

Dr. Ho’s clinical and research interests include dermatologic therapeutics and oncology, and brings his experience in pharmacology to his research and patients. He has conducted over 60 studies since 1989, and has published extensively: over 80 journal publications, 60 papers presented at conferences, and 11 chapters co-authored in textbooks. As part of his work at the BC Cancer Agency, Dr. Ho is closely involved in cancer prevention campaigns such as the “‘Sun Awareness Week” and “Mole Patrol”.

Research Studies

Psoriasis

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Psoriasis

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis

Psoriasis

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Dermatitis

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

Psoriasis

A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)

Psoriasis

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (VOYAGE 1)

Psoriasis

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

Dermatitis

Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis

Psoriasis

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Psoriasis

Chronic Plaque Psoriasis (Ps) Registry

Psoriasis

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy